Trump issues proclamation for 100% tariff on certain pharmaceutical imports starting September 29
GS2Polity · Governance · IR· India's bilateral relations· Prelims + Mains·
Trade barriers and supply chain resilience: a GS2 International Relations and GS3 Economic case study.
Why in news
President Donald Trump issued a proclamation to impose a 100% tariff on certain patented pharmaceutical imports and ingredients starting September 29 to encourage domestic production.
Background
The proclamation targets patented pharmaceutical imports and associated ingredients under Section 232 of the Trade Expansion Act. Exemptions are provided for generic pharmaceutical products and speciality drugs for rare medical conditions from India and 19 other countries.
Facts for Prelims
- FactTariff rate: 100% on certain patented pharmaceutical imports and ingredients.
- FactEffective date: September 29.
- Act / BillSection 232 of the Trade Expansion Act: Basis for the tariff proclamation.
- FactExemptions: Generic pharmaceutical products and speciality drugs for rare medical conditions from India and 19 other countries.
- FactEligible exempt products: drugs for rare diseases, infertility treatments, cell therapies, gene therapies, antibody-drug conjugates (ADCs), and animal pharmaceuticals.
Prelims practice question
With reference to the recent US pharmaceutical tariff proclamation, consider the following statements:
- Generic pharmaceutical products from India are included in the 100% tariff.
- The proclamation imposes a 100% tariff on certain patented pharmaceutical imports and ingredients.
- The proclamation is issued under Section 232 of the Trade Expansion Act.
Which of the statements given above is/are correct?
- (a)2 only
- (b)1 and 3 only
- (c)2 and 3 only
- (d)1, 2 and 3
Show answer
Answer: (c) 2 and 3 only — Statements 2 and 3 are correct. Statement 1 is incorrect: Generic pharmaceutical products from India are provided exemptions.
For Mains
Q. Discuss how unilateral trade barriers on pharmaceutical imports can impact global healthcare supply chains and India's position as a global pharmacy.
Dimensions to cover in your answer
- Trade friction: Impact of 100% tariffs on the cost of patented medicines and R&D investment
- Strategic autonomy: Balancing domestic production incentives with global supply chain dependencies for rare disease drugs
Keywords: Trade barriers · Pharmaceutical trade · Section 232 · Supply chain resilience · Domestic production
More International Relations notes
- Russian drone strike on MV ROYAD MAMMADOV kills captain and one crew member · 6 October 2026
- India and UAE armies begin Exercise Mountain Guardian 2026 in Uttarakhand · 6 October 2026
- PM Tarique Rahman has not ruled out a visit to India through bilateral framework · 6 October 2026
- Nepal suspends search operations 40 days after floods killed 1,455 people · 6 October 2026
- U.S. Ambassador Sergio Gor hosts Admiral Paparo to discuss U.S.-India Major Defence Partnership · 6 October 2026
- Jaishankar calls for UN reforms and dialogue to resolve Russia-Ukraine conflict · 5 October 2026
Something wrong, or something missing?
Spotted a mistake in a note, or want a topic, format or PDF that would help your preparation? Write to us. We read every mail and fix errors fast.
This note is generated automatically from SatyaDheesh's news feed and mapped to the UPSC CSE syllabus. Check facts against the original report or PIB before using them in an answer.